Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (14239)	11/19/2004 7:57:03 PM
From: former_pgs	Read Replies (4) of 52153

>How wonderful to know you're around!..thanks..I knew about the failed naive/chemo combo but not the EGFR status differences..< I'm not trying to be rude or condescending in any way, but I'm really amazed to read this. How could investors be shocked that an EGF-R inhibitor is practically inactive in patients with tumours that do not express EGF-R? How could anyone expect otherwise?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next